drugset / Trial / NCT05849129

Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer

NCT05849129

RandomizedParallel-groupQuadruple-blindSupportive care

Summary

This is a two arm RCT evaluating the effect of intravenous vitamin C versus placebo in patients with incurable non-small cell lung cancer. Participants in both arms will be receiving platinum doublet chemotherapy with or without concurrent immunotherapy as standard care. We plan to enroll 90 patients over 5 years.

Timeline

Start
2024-10-01
Primary completion
2030-10-01
Completion
2031-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Vitamin C Other / unclassified 1 g/kg Intravenous

Indications